DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category DRTS

Alpha Tau

Alpha Tau Medical ( $DRTS ) : Japan Approval, Pancreatic DDW 2026, GBM Optionality and a Technical Setup That Finally Looks Awake

Alpha Tau Medical is no longer just a quirky radiotherapy story that biotech tourists glance at and move on from. It now has a first non-Israeli approval in Japan, five U.S. trials running in parallel, a live pancreatic catalyst at DDW 2026, a GBM program that can materially alter the narrative, a modular PMA path in recurrent cSCC, insider-heavy ownership, and a chart that appears to be compressing directly beneath a multi-year decision zone.

Alpha Tau Medical Ltd ($DRTS)

Alpha Tau Medical is trying to build an entire platform around one idea: using very short-range, high-energy alpha particles to burn tumors from inside the lesion, instead of bathing a large region of the body in external radiation. With the Japanese Ministry of Health, Labour and Welfare (MHLW) now granting full Shonin marketing approval for Alpha DaRT in unresectable, locally advanced or locally recurrent head and neck cancer, the company has just obtained its first real proof that regulators outside Israel are willing to treat this as a commercial therapy, not only an experimental one.

DRTS Alpha Tau Medical Ltd Jan Update

We wrote our original bullish editorial at the very end of December 2025, when the stock was still trading around five dollars and largely under the radar. January brought ASCO GI pancreatic data, a first PMA module to the FDA, a shareholder letter and a sharp re-rating. Here we revisit the thesis, check the fundamentals and map the next catalysts. Educational only, not investment advice.